

In response to NNPDF's prior queries about a compassionate use program for olipudase alfa, I would like to share with you that Sanofi Genzyme has now submitted a protocol to US Food & Drug Administration (FDA) for a managed access program cohort for olipudase alfa in the United States for certain patients with ASMD. Sanofi Genzyme will provide the link to ClinicalTrials.gov when available.

Kate Tighe

Head, US Public Affairs & Patient Advocacy – Rare Diseases

Sanofi Genzyme



MAT-US-2103338 v 1.0 04/2021